ATC (Anatomical Therapeutic Chemical Classification)
CAS registry number (Chemical Abstracts Service)
Alpha-4 beta-7 integrin inhibitor
immunoglobulin G1-kappa, anti-[Homo sapiensalpha4beta7 integrin (lymphocyte Peyer's patch adhesion molecule 1, LPAM-1)], humanized monoclonal antibody; gamma 1 haevy chain (1-451)[humanized VH (Homo sapiensIGHV1-3*01 (84.70%)-(IGHD)IGHJ4*01)[8.8.14](1-121 (WHO)
- Vedolizumabum (Latin)
- Vedolizumab (German)
- Védolizumab (French)
- Vedolizumab (Spanish)
- Vedolizumab (OS: USAN)
- UNII-9RV78Q2002 (IS)
Takeda, Australia; Takeda, Bosnia & Herzegowina; Takeda, Finland; Takeda, Ireland; Takeda, Poland; Takeda Canada, Canada; Takeda France, France; Takeda Pharma, Austria; Takeda Pharma, Switzerland; Takeda Pharma, Denmark; Takeda Pharma, Sweden; Takeda Pharma, Slovenia; Takeda Pharmaceuticals U.S.A, United States; Takeda UK, United Kingdom
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
|WHO||World Health Organization|
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.